ArticleAnnals of surgical oncology2025
SPRY1 Interaction with CBL Promotes Vimentin Stabilization to Enhance Malignant Progression and Metastasis in Wilms Tumor.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSPRY1 from the Sprouty family is frequently overexpressed in many tumors and is accompanied by poor prognosis and metastatic progression. However, its role in the tumorigenesis of Wilms tumor (WT) remains unknown. The aim of this study is to elucidate the functional role of SPRY1 in the oncogenesis of Wilms tumor. MATERIALS AND
methodsPublic datasets and clinical WT samples were collected to evaluate the expression and clinical significance of SPRY1 in patients with WT. Chip-qPCR, CCK8, transwell assays, wound-healing assay, immunohistochemistry (IHC), immunofluorescence, and a subcutaneous xenograft tumor model were utilized to examine the biological function of SPRY1. Biogrid prediction, coimmunoprecipitation (Co-IP), and functional gains and loss experiments revealed the downstream regulatory mechanism of SPRY1.
resultsWe showed that high expression of SPRY1 was associated with poor prognosis of patients with Wilms tumor in public datasets, which was verified by cell lines. SPRY1 knockdown significantly inhibited cellular proliferation, migration, and invasion both in vitro and in vivo. The E3 ubiquitin ligaseCBL was identified as a target protein that interacts with SPRY1 with the aid of the Biogrid database. Mechanistically, SPRY1 disrupted CBL-vimentin binding by competing with vimentin for binding to CBL in an enzyme-independent manner. Upregulation of SPRY1 increases combination with CBL, reducing vimentin ubiquitination by CBL and promoting vimentin accumulation.
conclusionsCollectively, these findings indicate that the accumulation of SPRY1 led to stabilization of vimentin by binding to CBL, thus resulting in hyperactivation of the EMT pathway to promote carcinogenesis in Wilms tumor. This provides a potential strategy to treat Wilms tumor targeting the SPRY1-CBL-vimentin axis.
Indexed as
Identifiers
40887570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.